These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 19414316)

  • 21. Pancreatic cancer in Illinois. A report by 88 hospitals on 2,401 patients diagnosed 1978-84.
    Sener SF; Fremgen A; Imperato JP; Sylvester J; Chmiel JS
    Am Surg; 1991 Aug; 57(8):490-5. PubMed ID: 1928991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect induced by dendritic cell (DC)-based immunotherapy against peritoneal dissemination of the hamster pancreatic cancer.
    Takigawa Y; Akiyama Y; Maruyama K; Sugiyama K; Uchida E; Kosuge T; Ueda M; Kitajima M; Yamaguchi K
    Cancer Lett; 2004 Nov; 215(2):179-86. PubMed ID: 15488636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma.
    Lygidakis NJ; Ziras FA; Kyparidou E; Parissis J; Papadopoulou P; Venetsanou B
    Hepatogastroenterology; 1995; 42(6):1039-52. PubMed ID: 8847017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy for unresectable pancreatic cancer].
    Yahara N; Oka M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):390-7. PubMed ID: 11915728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
    Caprotti R; Brivio F; Fumagalli L; Nobili C; Degrate L; Lissoni P; Parolini D; Messina G; Colciago M; Scotti M; Uggeri F
    Anticancer Res; 2008; 28(3B):1951-4. PubMed ID: 18630487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy].
    Jensen HA; Nielsen HO; Jensen JD; Fristrup CW; Nielsen M; Pfeiffer P
    Ugeskr Laeger; 2008 Feb; 170(8):639-41. PubMed ID: 18364156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer.
    Tani M; Kawai M; Terasawa H; Ina S; Hirono S; Shimamoto T; Miyazawa M; Uchiyama K; Yamaue H
    J Hepatobiliary Pancreat Surg; 2007; 14(6):545-50. PubMed ID: 18040618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
    Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
    Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer?
    Lygidakis NJ; Papadopoulou P
    Hepatogastroenterology; 1995; 42(5):587-96. PubMed ID: 8751219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
    Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
    Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
    Yachida S; Fukushima N; Sakamoto M; Matsuno Y; Kosuge T; Hirohashi S
    Br J Surg; 2002 May; 89(5):573-8. PubMed ID: 11972546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators.
    Cho C; Wust P; Hildebrandt B; Issels RD; Sehouli J; Kerner T; Deja M; Budach V; Gellermann J
    Int J Hyperthermia; 2008 Aug; 24(5):399-408. PubMed ID: 18608591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2.
    Bevanda M; Orsolic N; Basic I; Vukojevic K; Benkovic V; Horvat Knezevic A; Lisicic D; Dikic D; Kujundzic M
    Int J Hyperthermia; 2009 Mar; 25(2):132-40. PubMed ID: 19337913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells].
    Shimizu K; Tamura K; Yamada M; Okamoto Y; Miyao Y; Park K; Matsui Y; Hayakawa T; Takimoto H; Mogami H
    No To Shinkei; 1989 Oct; 41(10):991-5. PubMed ID: 2605046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.